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ABSTRACT
Wedemonstratethefeasibilityofusingglassmicrobeadswithaholographicbarcode
identiﬁer to track DNA specimens in the molecular pathology laboratory. These
beads can be added to peripheral blood specimens and are carried through auto-
mated DNA extraction protocols that use magnetic glass particles. We found that an
adequate number of microbeads are consistently carried over during genomic DNA
extraction to allow specimen identiﬁcation, that the beads do not interfere with the
performance of several diVerent molecular assays, and that the beads and genomic
DNA remain stable when stored together under regular storage conditions in the
molecular pathology laboratory. The beads function as an internal, easily readable
specimen barcode. This approach may be useful for identifying DNA specimens and
reducingerrorsassociatedwithmolecularlaboratorytesting.
Subjects Pathology
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INTRODUCTION
Events that negatively impact, or could negatively impact, patient care because of quality
concerns with DNA-based clinical genetic testing are rare, occurring in <0.5% of tests
performed (Hofgartner & Tait, 1999). Despite this low rate of error, further reduction
remains a priority of clinical laboratories. Errors can occur in all phases of testing
(pre-analytical,analytical,andpost-analytical),withthemajorityofproblemsoccurringin
thepre-analyticalphase.Thisemphasizestheimportanceofqualityassuranceinallphases
of testing. In this brief report, we describe the use of small glass microbeads containing
a unique numeric code to barcode DNA eluates from peripheral blood specimens. The
beads can be added directly to the peripheral blood specimens and are carried through
automated DNA extraction protocols that use magnetic glass particles. A bead reader
system can identify the bead number in the specimen, which can function as an internal
barcode for specimen identiﬁcation. This can be used to check the identity of DNA
specimens that, for example, give unexpected results. Likewise, this approach could be
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clinical molecular laboratory. PeerJ1:e91; DOI10.7717/peerj.91used to check specimens at a set interval as part of the laboratory quality assessment
program. Incorporation of this microbead system directly into blood draw tubes could be
usedtoimmediatelybarcodethespecimenveryearlyinthepre-analyticalphaseoftesting.
Preliminary data suggest that this approach can be used to track DNA specimens without
interfering with DNA storage or downstream molecular testing. With the increased use of
nucleic acid testing to guide precision or personalized medicine, this method provides a
uniqueapproachtodecreaselaboratoryerror.
MATERIALS AND METHODS
Specimens
TheuseofperipheralbloodspecimensinthisstudywasapprovedbyaStanfordUniversity
IRB.
VeraCode glass microbeads
VeraCodemicrobeadswereprovidedbyIllumina,Inc.(SanDiego,CA)inmicrocentrifuge
tubes,eachcontainingapproximately40,000beadsin70%ethanol.VeraCodemicrobeads
are cylindrical glass beads measuring 240 microns in length by 28 microns in diameter.
A digital holographic element containing a numeric code is embedded within the beads
servingasauniqueidentiﬁer.Whenexcitedbyalaser,eachbeademitsauniquecodeimage
thatisdetectedbyIllumina’sBeadXpressReaderSystem.
DNA extraction with VeraCode microbeads
Tubes containing the VeraCode microbeads were centrifuged in a microcentrifuge at
greater than or equal to 10,000 rpm. Most of the 70% ethanol was removed from the
tubes, leaving 150 L of residual 70% ethanol with the 40,000 beads. Subsequently,
200 L of peripheral blood was added to the 70% ethanol and bead mixture using a
1 mL pipet and mixed thoroughly. The peripheral blood specimens containing the bead
mixtures were then extracted on the Qiagen BioRobot EZ1 Workstation using the EZ1
DNABlood350LKit(Valencia,CA)followingthemanufacturer’sstandardprotocolwith
a 200 L elution volume. The eluate containing the VeraCode beads was transferred to the
well of a 96-well round bottom microplate (Corning Inc., Corning, NY). A KingFisher
96 pin magnet head with a tip comb (Thermo Fisher Scientiﬁc, Waltham, MA) was
used to remove residual Qiagen magnetic beads that could potentially interfere with the
BeadXpressReaderSystem.
Determination of the number of VeraCode microbeads carried
through the DNA extraction process
On seven independent days, VeraCode microbeads were added to three peripheral blood
specimens.AsisoutlinedinTable1,thesamesetsofperipheralbloodspecimenswereused
for two or three days. Following the extraction process described in the above section, the
beads were transferred to a 76.2  25.4 mm standard glass microscope slide and a 24 
50 mm cover glass was used. The VeraCode microbeads were counted using a microscope
under100magniﬁcation.
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Days1,2and3 Days4and5 Days6and7
Specimen1 Specimen2 Specimen3 Specimen4 Specimen5 Specimen6 Specimen7 Specimen8 Specimen9
534 464 743 108 203 135 231 295 408
1096 778 362 168 242 83 140 174 101
105 279 257
Utilization of VeraCode microbeads for specimen identiﬁcation
Six peripheral blood specimens submitted for cystic ﬁbrosis gene mutation testing
underwent DNA extraction as described above with and without VeraCode microbeads
added to the peripheral blood; beads containing a unique bead identiﬁcation code were
added to each peripheral blood specimen. DNA eluates with and without the beads were
tested with the Cystic Fibrosis Genotyping Assay (Abbott Laboratories, Abbott Park,
IL). In brief, this assay detects 32 cystic ﬁbrosis transmembrane conductance regulator
(CFTR) gene mutations via multiplex PCR ampliﬁcation and oligonucleotide ligation
assays followed by detection via capillary electrophoresis on an Applied Biosystems
3130xl Genetic Analyzer (Life Technologies Corporation, Carlsbad, CA). The resulting
electropherograms were interpreted and evaluated for equivalency by two molecular
pathologists (JDM and IS). A plate containing the residual DNA specimens with and
withoutthebeadswascovered,frozen,andshippedtoIllumina,Inc.tousetheBeadXpress
Reader System in order to determine the bead number associated with each specimen.
We required that 20 beads with the same barcode be detected by the instrument for
deﬁnitive specimen identiﬁcation for all experiments. In internal experiments, Illumina
has determined that the bead mis-identiﬁcation rate is under 0.5%, suggesting that a
requirementfor20beadsforsampleidentiﬁcationismorethansuYcient.
We selected six independent peripheral blood specimens from individuals without a
knowncancerdiagnosis,andforthreeofthespecimens,wespikedinacelllinecontaining
the IGH-BCL2 translocation at a 1:10,000 dilution to generate positive sensitivity controls
near the lower limit of detection of the IGH-BCL2 translocation assay. DNA extraction
was performed as described above with and without VeraCode microbeads added to each
of the six peripheral blood specimens. Beads containing a unique bead identiﬁcation
code were added to each peripheral blood specimen. DNA eluates with and without the
beads were tested with our assay used to detect IGH-BCL2 translocations involving the
major breakpoint region, minor cluster region and intermediate cluster region of BCL2.
This assay uses multiplex, nested PCR followed by detection of ampliﬁcation products via
agarose gel electrophoresis. The resulting gel photographs were interpreted and evaluated
for equivalency by two molecular pathologists (JDM and IS). A plate containing the
residual DNA specimens with and without the beads was covered, frozen, shipped to
Illumina, Inc., and scanned on the BeadXpress Reader System in order to determine the
unique bead identiﬁcation code associated with each specimen. The group using the
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beadidentiﬁcationcodewasusedineachsample.
Examination of VeraCode bead and DNA stability
Three peripheral blood specimens were used for this portion of the study – each was
submitted to our molecular pathology laboratory for testing with either the Cystic
Fibrosis Genotyping Assay described above, the quantitative JAK2 V617F MutaQuant
assay (Ipsogen, Stamford, CT), or our laboratory-developed Fragile X syndrome assay.
TheJAK2V617FMutaQuantassayisanallele-speciﬁc,real-timePCRassaythatquantiﬁes
both JAK2 V617F and corresponding wild-type alleles. Our laboratory-developed Fragile
X syndrome assay uses PCR optimized for GC-rich amplicons followed by capillary
electrophoresis on an Applied Biosystems 3130xl Genetic Analyzer to detect .CGG/n
trinucleotiderepeatexpansionsinthe50 untranslatedregionofFMR1.Eachspecimenwas
assignedauniquebeadidentiﬁcationcode.Beadswiththisidentiﬁcationcodewereadded
to four aliquots of each peripheral blood specimen, and the specimens were extracted
as described above. Eluates containing the beads were incubated at 25C. Two aliquots
of each specimen were removed after 50 days and 90 days. Each specimen was re-tested
using the same assay for which the specimen was originally submitted, and the results
were interpreted and evaluated for equivalency by two molecular pathologists (JDM and
IS). A plate containing the DNA specimens with beads was covered, frozen, and shipped
to Illumina, Inc. to use the BeadXpress Reader System in order to determine the bead
identiﬁcationcodeassociatedwitheachspecimen.ThegroupusingtheBeadXpressReader
Systemwasblindedtowhichbeadidentiﬁcationcodewasaddedtoeachspecimen.
Accelerated stability calculations used the Q10 model, a simpliﬁcation of the Arrhenius
equation approach (Hemmerich, 1998). In this experiment, the method predicts the
stability of a well-characterized reagent at 4C based on stability at the elevated
temperature of 25C. The Q10 value equals 2. Under the Q10 model, the time relationship
between the accelerated temperature (Taccel) and the storage temperature (Tstorage) is
given by the equation Q Factor D 2..Taccel Tstorage/=10/; therefore, for this experiment the
QFactor D 2..25 4/=10/ D 4:3.Onedayat25Cisequivalentto4daysat4C.
RESULTS
We initially observed that VeraCode microbeads containing a holographic identiﬁcation
code could be added to whole blood specimens and subsequently carried through the
genomic DNA extraction process on instruments that use magnetic glass particles. We
observed equivalent results using the BioRobot EZ1 Workstation (Qiagen) and MagNA
Pure LC (Roche Diagnostics Corporation, Indianapolis, IN), and used the BioRobot
EZ1 Workstation for subsequent work described in this manuscript. Given potential
applications for specimen identiﬁcation and quality assurance in the molecular pathology
laboratory,weperformedasetofexperimentsdesignedtoevaluatethepotentialfeasibility
of using the VeraCode microbeads to track specimens in a clinical molecular laboratory.
We found that a suYcient number of microbeads are consistently carried over during
genomic DNA extraction to allow specimen identiﬁcation, that the beads do not interfere
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Specimen DNAconcentrationwhen
extractedwithoutbeads
DNAconcentrationwhen
extractedwithbeads
1 43 ng=L 22 ng=L
2 51 ng=L 33 ng=L
3 44 ng=L 24 ng=L
4 73 ng=L 44 ng=L
5 49 ng=L 25 ng=L
6 79 ng=L 53 ng=L
with several diVerent molecular assays, and that the beads and genomic DNA are stable
whenstoredtogetheroverextendedperiodsoftime.
We ﬁrst evaluated if a suYcient number of microbeads would be carried through the
DNAextractionproceduretobereadbytheBeadXpressReaderSystem(Illumina),thereby
allowing identiﬁcation of the specimen being tested. Although in practice even a single
bead can be read and detected by the system, we conservatively established that at least 20
microbeadswiththesameidentiﬁcationcodeshouldbepresenttoallowreliabledetection
with this system. As is shown in Table 1, well in excess of 20 microbeads were carried
through the extraction procedure using multiple diVerent specimens over multiple days.
In total, 21 individual extractions were evaluated, yielding a median of 242 microbeads
per extraction (range 83–1096). Given that 40,000 microbeads are added to the initial
whole blood aliquot, the eYciency of carryover to the DNA eluate is low, but a suYcient
numberofbeadsareconsistentlytransferredtoallowdetectionbythesystem.Ofnote,the
measured DNA yield of extractions that included the beads was generally lower than that
of the same specimen extracted without microbeads – average of 57 ng=L without beads
and 34 ng=L with beads (Table 2). PCR can be reproducibly performed on nanogram
quantities of genomic DNA, and our laboratory generally uses between 1 and 1,000 ng
of genomic DNA per PCR reaction. Therefore, the DNA concentration and total yield
were for suYcient for molecular testing, and we usually hadmicrograms of residual DNA.
It is unclear why the presence of the microbeads during the extraction process reduced
the amount of DNA in the eluate. It is possible that some of the DNA was bound to the
glass microbeads and therefore not available to be measured in solution. Collectively,
these data indicate that a suYcient number of microbeads are carried through the DNA
extractionproceduretobereadbytheBeadXpressReaderSystem,andthatinclusionofthe
microbeadsdoesnotappreciablyimpacttheDNAextractionprocess.
We subsequently examined whether inclusion of the VeraCode microbeads aVected
the performance of two clinical assays commonly performed in our molecular pathology
laboratory and whether the beads could be used to track DNA specimens within our
laboratory. We hypothesized that the beads would not interfere with molecular assays
because they are commonly used in related genotyping assays (Lin et al., 2009). Six
peripheral blood specimens submitted for CFTR mutation testing underwent DNA
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Specimen
number
Beadnumber
added
Beadnumber
detected
Assay Assayresultwithmicrobeads
added
Assayresultwithoutbeads
added
Equivalent
ampliﬁcation
10 4096 4096 CF32 homozygous delF508 homozygous delF508 Yes
11 272 272 CF32 homozygous delF508 homozygous delF508 Yes
12 40 40 CF32 homozygous delF508 homozygous delF508 Yes
13 136 136 CF32 no mutations detected no mutations detected Yes
14 2560 2560 CF32 no mutations detected no mutations detected Yes
15 1040 1040 CF32 no mutations detected no mutations detected Yes
16 1040 1040 BCL2 IGH-BCL2 detected IGH-BCL2 detected Yes
17 2560 2560 BCL2 IGH-BCL2 not detected IGH-BCL2 not detected Yes
18 136 136 BCL2 IGH-BCL2 detected IGH-BCL2 detected Yes
19 40 40 BCL2 IGH-BCL2 not detected IGH-BCL2 not detected Yes
20 272 272 BCL2 IGH-BCL2 detected IGH-BCL2 detected Yes
21 4096 4096 BCL2 IGH-BCL2 not detected IGH-BCL2 not detected Yes
Notes.
CF32 – Abbott Laboratories Cystic Fibrosis Genotyping Assay; BCL2 – Laboratory-developed assay for detection of IGH-BCL2 translocations.
extraction with and without VeraCode microbeads added to the peripheral blood. A
unique bead identiﬁcation code was added to each peripheral blood specimen, essentially
adding a readily readable molecular barcode to the specimen. DNA eluates with and
without the beads were tested with our laboratory’s cystic ﬁbrosis carrier screening assay.
The resulting data were interpreted by two molecular pathologists, and the results of the
cystic ﬁbrosis assays were the same in the paired peripheral blood specimens with and
withoutthebeads(Table3).Inaddition,peakpositionsandheightswereequivalentinthe
specimens with and without beads (Fig. 1 illustrates a representative example), indicating
that the presence of the microbeads does not signiﬁcantly interfere with the performance
of this assay. Subsequently, members of our group blinded to which bead was added to
eachspecimensuccessfullyusedtheBeadXpressReaderSystemtoidentifythecorrectbead
identiﬁcationcodeoriginallyaddedtoeachspecimen(Table3).
We also performed a similar set of experiments to that described above with the cystic
ﬁbrosiscarrier assay,usingour laboratoryassay forthequalitative detectionofIGH-BCL2
translocations by PCR. As is seen in Table 3 and Fig. 2, the results were the same for all
six specimens tested and assay performance was equivalent. Likewise, we were able to
re-identifyinablindedmannerwhichbeadwasaddedtowhichspecimen.
The cystic ﬁbrosis and IGH-BCL2 experiments also allowed examination of time
required for operation of the BeadXpress Reader System. Since the plates containing
the specimens with microbeads can be directly loaded into a drawer in the BeadXpress
Reader System after thawing, minimal hands-on time is required for this step. Once the
instrument is initialized, the time to get results for 1, 12, or 96 specimens is approximately
5,10,and60min,respectively.
Finally, to examine the long-term stability of the VeraCode microbeads we used
accelerated stability experiments, and we also evaluated the integrity of the DNA
under these conditions. We selected three peripheral blood specimens submitted to our
Merker et al. (2013), PeerJ, DOI 10.7717/peerj.91 6/10Figure 1 Representative capillary electropherograms from a multiplex PCR ampliﬁcation and oligonucleotide ligation assay to detect 32
diVerent mutations in the CFTR gene. The presence of beads during the extraction process and downstream steps (A) does not appear to aVect
either peak height or assay results when compared to analysis of the same specimen without beads (B). No CFTR mutations were detected in the
specimen with or without the beads and each of the peaks is present at the same position.
molecular pathology laboratory for testing with either the Cystic Fibrosis Genotyping
Assay, a quantitative JAK2 V617F MutaQuant assay, or our laboratory-developed Fragile
X syndrome assay. Beads with a number speciﬁc to each specimen were added to multiple
aliquots of each peripheral blood specimen, and DNA was extracted from the specimens.
Eluates containing the beads were incubated at 25C, which was our elevated storage
temperature. Using the Q10 model, one day at 25C is equivalent to just over four days
at or below 4C. Two aliquots of each specimen were removed from incubation at 25C
after 50 days and 90 days, which is projected to represent 4C incubation for 215 days and
387 days. Each specimen was re-tested using the same assay for which the specimen was
originallysubmitted,andtheresultswereequivalentinbothreplicatesatbothtimepoints.
In addition, the correct bead number associated with each replicate was identiﬁed in a
blinded manner. We note that the accelerated stability calculations using the Q10 model is
a conservative approach in the assignment of Q10 D 2. In addition, if this method is used
to calculate the stability of reagents stored at  15C or below, additional stability may be
conferred due to the phase transition. Collectively, these data indicate that the beads and
theDNAintheeluatearestableforatleastoneyearat4Candpossiblylongerwhenstored
frozen.
DISCUSSION
In this report, we evaluated the feasibility of using the VeraCode microbeads to track
DNA specimens in the clinical molecular laboratory. We found that a suYcient number
of microbeads are consistently carried over during genomic DNA extraction to allow
specimen identiﬁcation, that the beads do not appear to interfere with several diVerent
molecular assays, and that the beads and genomic DNA are stable when stored together
Merker et al. (2013), PeerJ, DOI 10.7717/peerj.91 7/10Figure 2 Agarose gel electrophoresis demonstrating control ampliﬁcation reactions for a PCR-based
IGH-BCL2 translocation assay. The presence of beads during the extraction process and downstream
steps does not signiﬁcantly aVect the control ampliﬁcation for this assay. This control amplicon is a
270 bp product derived from the F5 gene.
overextendedperiodsoftime.Thebeadsfunctionasaninternal,easilyreadablespecimen
barcode.This methodmayprovide anadditionalapproach toidentifyingDNA specimens
and minimizing errors associated with molecular laboratory testing. Presently, this
approach could be used to recheck the identity of DNA specimens that give unexpected
results or to check specimens at a set interval as part of the laboratory quality assurance
program. This would be a novel way to monitor for possible specimen mix-ups. Although
the hands-on time and scanning time are reasonable, our experience suggests that it
would not be practical to examine every specimen tested by a busy molecular pathology
laboratorywithourmethod.
WesuggestthatthisapproachrepresentsanovelmechanismtotrackDNAspecimensin
themolecularpathologylaboratory,andthedatapresentedprovideaproofofconceptthat
suchanapproachispossible.However,acoupleoftechnicalissuesrelatedtothemicrobead
size currently limit the potential utility of this approach. The present microbeads are too
largetoco-elutewithDNAusingcolumn-basedextractionmethods,andconsequentlythis
microbeadtrackingsystemcannotbeusedwithmanyDNAandRNAextractionmethods.
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a suYcient number of beads from the DNA eluate to downstream assay steps due to the
microliter volumes typically used during molecular testing. As an example, we found that
addition of DNA from the tube containing the DNA eluate with microbeads to a standard
PCR reaction did not reliably result in the transfer of a suYcient number of beads to be
detected by the barcode reader. However, further manipulation of the beads or extraction
process may allow for these limitations to be overcome and for this application to become
morebroadlyapplied.
Other factors must be addressed and studies performed before the method can be
incorporated into routine clinical practice. First, the BeadXpress Reader System and
associatedVeraCodemicrobeadswerenotdesignedforthisapplication.Consequently,the
ﬁnal retail list price of the reader, $98,000, was likely higher than an instrument designed
solely for applications described in this manuscript. Furthermore, the conﬁguration of
VeraCode microbeads used in this study was custom prepared and is not commercially
availableatthistime.Second,weevaluatedthismethodtotrackDNAspecimensextracted
from peripheral blood. For this method to be applied to all areas of the molecular
pathology laboratory, further examination of RNA extracted specimens would need
to be performed. Likewise, specimens other than peripheral blood would need to be
evaluated, and in the case of tissue specimens, the protocol would likely need to be
modiﬁed to avoid, among other issues, destruction of the glass microbeads during the
homogenization process. Third, we examined four assays in this study and a thorough
validation would require examination of a larger number of qualitative and quantitative
assayswithassociatedstatisticalassessmentofinterference.
In summary, we have demonstrated a proof of concept that glass microbeads with
a holographic numeric code can be used to barcode DNA eluates from peripheral
blood specimens. This represents a novel way to track DNA specimens in the molecular
pathology laboratory, and we suggest that with appropriate modiﬁcations and further
evaluation such an approach could minimize the potential for errors associated with
molecularlaboratorytesting.
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